Cyclovirobuxine D inhibits growth and progression of non‑small cell lung cancer cells by suppressing the KIF11‑CDC25C‑CDK1‑CyclinB1 G2/M phase transition regulatory network and the NFκB/JNK signaling pathway
Open Access
- 15 March 2023
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 62 (5) , 1-21
Abstract
Lung cancer is the leading cause of cancer‑related mortality worldwide. Non‑small cell lung cancer (NSCLC) is the most common pathological subtype of lung cancer and is associated with low 5‑year overall survival rates. Therefore, novel and effective chemotherapeutic drugs are urgently required for improving the survival outcomes of patients with lung cancer. Cyclovirobuxine D (CVB‑D) is a natural steroidal alkaloid, used for the treatment of cardiovascular diseases in Traditional Chinese Medicine. Several studies have also demonstrated the antitumor effects of CVB‑D. Therefore, in the present study, the therapeutic effects of CVB‑D in lung cancer and the underlying mechanisms were investigated using the in vivo xenograft model of NSCLC in nude mice and in vitro experiments with the NSCLC cell lines. Bioinformatics analyses of RNA‑sequencing data, and cell‑based functional assays demonstrated that CVB‑D treatment significantly inhibited in vitro and in vivo NSCLC cell proliferation, survival, invasion, migration, angiogenesis, epithelial‑to‑mesenchymal transition and G2/M phase cell cycle. CVB‑D exerted its antitumor effects by inhibiting the KIF11‑CDK1‑CDC25C‑cyclinB1 G2/M phase transition regulatory oncogenic network and the NF‑κB/JNK signaling pathway. CVB‑D treatment significantly reduced the sizes and weights and malignancy of xenograft NSCLC tumors in the nude mice. In conclusion, the present study demonstrated that CVB‑D inhibited the growth and progression of NSCLC cells by inhibiting the KIF11‑CDK1‑CDC25C‑CyclinB1 G2/M phase transition regulatory network and the NF‑κB/JNK signaling pathway. Therefore, CVB‑D is a promising drug for the treatment of NSCLC patients.Keywords
This publication has 81 references indexed in Scilit:
- JNK signalling in cancer: in need of new, smarter therapeutic targetsBritish Journal of Pharmacology, 2013
- Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cellsOncology Reports, 2013
- The complexity of NF-κB signaling in inflammation and cancerMolecular Cancer, 2013
- JNK-mediated Phosphorylation of Cdc25C Regulates Cell Cycle Entry and G2/M DNA Damage CheckpointJournal of Biological Chemistry, 2010
- Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to MitosisDevelopmental Cell, 2010
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- NF-kappaB: a potential target for cancer chemoprevention and therapyFrontiers in Bioscience-Landmark, 2008
- Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapyLung Cancer, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Control of mitosis by changes in the subcellular location of cyclin-B1–Cdk1 and Cdc25CCurrent Opinion in Cell Biology, 2000